Biographical Sketch
Brian I. Rini, MD, is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor
Oncology and Associate Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, Dr.
Rini’s work focuses on genitourinary malignancies.
Dr. Rini earned his medical degree at the Ohio State University College of Medicine in Columbus, Ohio.
After completing a residency program in internal medicine at University of Chicago Hospitals in Illinois,
Dr. Rini was awarded a fellowship in hematology and oncology at the University of Chicago. Dr. Rini was
an Assistant Professor at the University of California San Francisco before moving to Cleveland Clinic.
At Cleveland Clinic, Dr. Rini’s primary research has been in renal cell carcinoma (RCC) and prostate
cancer, with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini’s research has been
published in peer-reviewed journals that include Journal of the National Cancer Institute, Journal of
Clinical Oncology, Cancer, Lancet and JAMA. He is a member of the editorial boards of Journal of Clinical
Oncology, Cancer and British Journal of Urology.
Certified in Medical Oncology by the American Board of Internal Medicine, Dr. Rini is active in numerous
professional organizations, including the American Society of Clinical Oncology (ASCO), American
Association for Cancer Research and the Kidney Cancer Association National Medical Advisory Board. He
serves on the ASCO Board of Experts and on the External Review Board for the ASCO Cancer Therapy
Evaluation Program.
Specialty Interests
anti-angiogenic therapy, genitourinary oncology, immunotherapy, Prostate Cancer, renal cell carcinoma
Awards & Honors
Cleveland's Best Doctors, 2005, 2006, 2007
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 7/31/2008, Dr.
Rini has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Rini receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Genentech, Inc.
Pfizer Inc.
Wyeth Pharmaceuticals Inc.
Novartis
